Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.
Age over 40 years.
Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.
Voluntarily participating and signed written informed consent.
Pregnant or lactating women.
Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).
History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.
History of blood transfusion within 7 days prior to blood collection.
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor
Nanjing Geneseeq Technology Inc.
Collaborator